DolPHIN2 |

Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.

image source: pexels

The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy

The team at the Infectious Diseases Institute, Kampala

DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.

How we work

About DolPHIN 2

Read about the challenges that the DolPHIN 2 project seeks to address and why.

The DolPHIN 2 Consortium

Learn more about our multinational research consortium, comprising partners in Europe and sub-Saharan Africa.

Community Voices

Collaboration with the community is at the heart of DolPHIN 2. Click here to learn more about our community engagement, and to hear from some of our study participants.

Resources

10 Mar 2021

DolPHIN2 Infographic

The DolPHIN 2 Clinical Trial is designed to yield high-quality evidence on the efficacy and safety of dolutegravir in late presenting pregnant women, to allow definitive recommendations for use of dolutegravir to reduce MTCT in this high-risk scenario.

Video

03 Dec 2019

HIV on Trial

Meet our research team, hear from some of our research participants and learn more about the DolPHIN story so far.

Video

28 Nov 2019

They become strong when they see me doing this

Jackie Kyeyune, a peer mother living with HIV, discusses how she uses her lived experience to support and inspire the DolPHIN 2 trial participants.

Video

28 Nov 2019

Trial Management at the Ugandan site

Dr Kenneth Kintu, trial manager at the IDI site, discusses the challenges and rewards of the study, and his hopes for the future

Video

View all Resources

News

The Ugandan Team Celebrates World Breastfeeding Week

08 Aug 2019

DolPHIN-2 presents primary outcome analysis at CROI 2019

05 Mar 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

WHO released a statement on 18 May 2018 relating to a potential safety issue affecting women living with HIV using dolutegravir at the time of conception.

20 Jun 2018

View all News and Events

@UoLDolPHIN2 on Twitter

RT @CatrionaWaitt: Understanding medication safety in populations is essential, but often neglected. We were delighted to review pharmacovigilance in LMIC with a focus on Africa for @BritJClinPharm @stenolssonPV @GlobalPV_TGHN @wellcometrust https://t.co/ePYM16PmNo https://t.co/ogrdoT4Y1w

2 months 3 weeks ago

RT @justinchiong: We're recruiting for a Senior Clinical Lecturer in Infection Pharmacology. Apply here - https://t.co/Za66B8ynrU

2 months 3 weeks ago

RT @CatrionaWaitt: @UoLDolphin2 : it is great to end the year with protocol training for a new phase of the study. After lockdowns and challenges, such milestones feel even more special and worthy of celebration! https://t.co/Bhtr1Vbpn5

5 months 1 week ago

Watch “DolPHIN2 Trial: A Chance to Save Two Lives? Testing HIV Drugs in Pregnant Women.” on https://t.co/ImWwQgdwSf #WorldAidsDay2021

5 months 3 weeks ago

RT @CatrionaWaitt: Celebrating @UoLDolphin2 on #WorldAidsDay2021 It is essential that drugs are studied in the populations where they are to be used, and around 1.3 million women living with HIV become pregnant each year. Equity of access to research = better outcomes for communities. https://t.co/XPsnV5JSP9

5 months 3 weeks ago

On #WorldAidsDay2021 thinking of the women and infants who have volunteered to take part in DolPHIN2 to further our understanding of #HIV treatment in #pregnancy https://t.co/ZlO6fD0Orv

5 months 3 weeks ago

RT @hivinteractions: Less than one week to go for #LMAP2021! Still time to register (for free), and we have a great programme lined up. LMAP 2021 is also CPD accredited. Visit https://t.co/T4s92gmBjK for more info https://t.co/9OIfBUBrBI

6 months 2 weeks ago

Congratulations to our DolPHIN2 investigators @AngelaColbers and David Burger on winning this @EACSociety award https://t.co/Mfn1y9PuNf

6 months 3 weeks ago

RT @At_The_EQUATOR: Important discussion @EACSociety #WAVE. If we are going to attain equity of access to research, we need to understand and address the barriers to participation. We can work together to improve this! @UoLDolphin2 @VirTUAL_UoL https://t.co/EWIrzbVEyx

6 months 3 weeks ago

RT @CatrionaWaitt: #EACS2021 Alexandra Calmy summarises landscape of increasing evidence for drug safety and efficacy in pregnancy and breastfeeding. Drawing from @pregnancyethics, highlights the need for a paradigm shift to increase equity of access to research. https://t.co/uL2td7SMw3

6 months 3 weeks ago

RT @tristanjbarber: brilliant @CatrionaWaitt @LivUni updating us on HIV, women and breastfeeding to conclude our pre conference educational day #YING #EACS2021 #crossingborders https://t.co/ZKPKsvEFQx

6 months 3 weeks ago

RT @hivinteractions: All ready at #EACS2021, come and find us at booth 14 https://t.co/IZxJSVALMf

6 months 3 weeks ago

The D2 Consortium

The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid.

DolPHIN2

Search

How we work

About DolPHIN 2

The DolPHIN 2 Consortium

Community Voices

Resources

DolPHIN2 Infographic

HIV on Trial

They become strong when they see me doing this

Trial Management at the Ugandan site

News

The Ugandan Team Celebrates World Breastfeeding Week

DolPHIN-2 presents primary outcome analysis at CROI 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

@UoLDolPHIN2 on Twitter

The D2 Consortium

University of Liverpool

Liverpool School of Tropical Medicine

Infectious Diseases Institute

University of Cape Town

Radboud University Medical Centre

Unitaid

Contact us

Follow us